The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! About 1.27M shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 11.56% since March 15, 2016 and is uptrending. It has outperformed by 6.08% the S&P500.
The move comes after 5 months positive chart setup for the $2.83B company. It was reported on Oct, 18 by Barchart.com. We have $30.31 PT which if reached, will make NASDAQ:HZNP worth $1.92 billion more.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on November, 4. They expect $0.67 EPS, up 13.56% or $0.08 from last year’s $0.59 per share. HZNP’s profit will be $105.11 million for 6.73 P/E if the $0.67 EPS becomes a reality. After $0.42 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 59.52% EPS growth.
Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 18 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, June 6 by Goldman Sachs. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, September 13. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Goldman Sachs on Thursday, December 17. The stock has “Buy” rating given by Mizuho on Friday, October 9. The firm earned “Neutral” rating on Wednesday, January 6 by Citigroup. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Market Perform” rating by Cowen & Co on Friday, September 16. Morgan Stanley upgraded the shares of HZNP in a report on Monday, July 11 to “Equal-Weight” rating. The rating was maintained by Mizuho on Tuesday, May 10 with “Buy”. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. The firm has “Mkt Outperform” rating by JMP Securities given on Wednesday, September 9.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.21, from 1 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
California Pub Employees Retirement System reported 336,000 shares or 0.01% of all its holdings. Prudential Fin Inc, a New Jersey-based fund reported 14,500 shares. Moreover, Moody Bank & Trust Trust Division has 0.02% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 18,265 shares. State Street Corp has 4.20M shares for 0.01% of their US portfolio. Ghost Tree Capital Limited Liability Co holds 1.19% or 250,000 shares in its portfolio. The New York-based Highbridge Management Limited Liability has invested 0.21% in Horizon Pharma PLC (NASDAQ:HZNP). Markston Int Limited Liability Company last reported 0% of its portfolio in the stock. Canada Pension Plan Investment Board has invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Amer Century Companies has 0% invested in the company for 238,054 shares. Blackrock owns 22,344 shares or 0% of their US portfolio. Turner Ltd Partnership reported 71,420 shares or 0.37% of all its holdings. New York State Common Retirement Fund has invested 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Utd Cap Fincl Advisers Limited Liability Company holds 0.02% or 104,339 shares in its portfolio. Swiss Comml Bank holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 243,556 shares. Diam has 403,067 shares for 0.1% of their US portfolio.
Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 2 selling transactions for $500,280 net activity. 2,900 shares were sold by SHERMAN JEFFREY W, worth $58,000. $442,280 worth of Horizon Pharma PLC (NASDAQ:HZNP) shares were sold by Nohria Virinder.
More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Investorplace.com which released: “Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!” on October 11, 2016. Also Globenewswire.com published the news titled: “Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and …” on October 13, 2016. Moodys.com‘s news article titled: “Moody’s affirms Horizon Pharma’s B2 CFR; downgrades unsec. rating to B3” with publication date: October 13, 2016 was also an interesting one.
HZNP Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.